Table 3.
Survival rates of UBC for different racial groups, stratified by gender, age, histologic type, stage at diagnosis, location and treatment.
| Survival rates | Total | NHW | HW | Black | API | P |
|---|---|---|---|---|---|---|
| Gender | 77.4 (77.1–77.6) | 78.2 (77.9–78.4) | 76.3 (75.1–77.3) | 62.5 (61.4–63.6) | 75.7 (74.5–76.9) | |
| Male | 79.0 (78.7–79.3) | 79.5 (79.2–79.8) | 78.9 (77.5–80.1) | 67.5 (66.1–68.9) | 77.5 (76.2–78.8) | <0.001 |
| Female | 72.5 (72.0–73.0) | 74.1 (73.6–74.6) | 69.01 (66.9–71.0) | 53.1 (51.2–54.9) | 70.2 (67.8–72.5) | <0.001 |
| Age group | ||||||
| 0–39 | 92.7 (91.9–93.5) | 94.0 (93.1–94.8) | 89.3 (85.6–92.1) | 83.0 (78.1–86.9) | 89.4 (83.5–93.2) | 0.001 |
| 40–64 | 84.1 (83.8–84.4) | 85.1 (84.8–85.4) | 81.4 (79.9–82.7) | 69.0 (67.4–70.5) | 85.1 (83.4–86.5) | <0.001 |
| 64–84 | 75.5 (75.2–75.8) | 76.3 (76.0–76.7) | 73.9 (72.2–75.4) | 59.3 (57.6–60.9) | 74.3 (72.6–75.8) | <0.001 |
| 85+ | 60.7 (59.3–62.0) | 61.5 (60.0–63.0) | 60.5 (53.8–66.6) | 45.0 (39.4–50.5) | 52.0 (46.4–57.3) | <0.001 |
| Histologic type | ||||||
| PTCC | 88.7 (88.4–89.0) | 89.0 (88.7–89.3) | 89.0 (87.6–90.1) | 80.7 (79.2–82.1) | 86.2 (84.8–87.5) | <0.001 |
| NPTCC | 57.4 (56.9–57.9) | 58.1 (57.6–58.7) | 56.1 (53.9–58.3) | 42.8 (41.0–44.6) | 61.3 (59.0–63.5) | <0.001 |
| Carcinoma | 47.0 (45.0–48.9) | 48.0 (45.8–50.1) | 50.2 (41.5–58.3) | 35.1 (287–41.6) | 37.9 (29.4–46.3) | 0.005 |
| SCC | 26.6 (25.0–28.3) | 28.0 (26.1–29.9) | 18.5 (12.9–25.1) | 20.2 (16.1–24.7) | 32.2 (22.1–42.7) | 0.003 |
| Stage at diagnosis | ||||||
| Stage II | 90.7 (90.4–90.9) | 90.9 (90.6–91.2) | 91.1 (89.9–92.2) | 83.6 (82.2–84.9) | 89.0 (87.7–90.2) | <0.001 |
| Stage III | 42.9 (42.4–43.5) | 43.4 (42.8–44.0) | 44.4 (41.9–46.9) | 33.8 (31.9–35.7) | 47.0 (44.3–49.7) | <0.001 |
| Stage IV | 5.9 (5.4–6.5) | 5.9 (5.3–6.5) | 7.0 (4.9–9.6) | 5.6 (4.1–7.4) | 5.1 (3.0–8.0) | 0.024 |
| Location | ||||||
| Trigone of bladder | 77.6 (76.6–78.5) | 78.2 (77.2–79.3) | 78.2 (73.5–82.1) | 62.6 (57.8-67.0) | 77.6 (72.6–81.8) | <0.001 |
| Dome of bladder | 71.6 (70.2–72.9) | 71.6 (70.1–73.0) | 77.3 (71.107–82.4) | 64.1 (58.8–68.9) | 75.1 (69.0–80.2) | <0.001 |
| Lateral wall of bladder | 85.4 (84.9–85.9) | 85.9 (85.4–86.4) | 85.6 (83.1–87.7) | 72.9 (70.1–75.5) | 84.5 (81.8–86.8) | <0.001 |
| Anterior wall of bladder | 71.0 (69.1–72.9) | 72.3 (70.2–74.3) | 63.4 (53.8–71.5) | 56.7 (48.8–63.8) | 71.5 (62.1-78.9) | <0.001 |
| Posterior wall of bladder | 83.0 (82.2–83.8) | 83.4 (82.4–84.2) | 85.8 (82.0–88. 8) | 70.8 (66.5–74.6) | 83.0 (78.9–86.3) | <0.001 |
| Bladder neck | 74.1 (72.6–75.5) | 75.3 (73.7–76.9) | 73.7 (67.0–79.2) | 56.2 (50.0–61.8) | 73.8 (67.2–79.3) | <0.001 |
| Ureteric orifice | 90.2 (89.2–91.0) | 90.40 (89.4–91.3) | 88.7 (83.6–92.2) | 87.4 (81.5–91.6) | 84.6 (78.7–89.0) | <0.001 |
| Urachus | 53.0 (47.2–58.4) | 56.3 (49.2–62.8) | 52.1 (33.1–68.2) | 39.6 (23.0–55.7) | 44.9 (27.4–61.0) | 0.192 |
| Overlapping lesion of bladder | 64.6 (63.9–65.4) | 65.4 (64.6–66.2) | 62.9 (59.4–66.1) | 52.2 (49.1–55.1) | 65.8 (61.9–69.3) | <0.001 |
| Bladder, NOS | 75.2 (74.8–75.6) | 76.2 (75.8–76.6) | 72.3 (70.5–74.0) | 59.2 (57.5–60.9) | 71.8 (69.9–73.7) | <0.001 |
| Treatment | ||||||
| SC | 68.7 (67.8–69.6) | 69.6 (68.6–70.6) | 66.7 (62.5–70.6) | 56.2 (52.2–60.0) | 73.9 (69.7–77.7) | 0.132 |
| Chemotherapy | 62.0 (60.4–63.4) | 63.6 (61.9–65.2) | 50.2 (42.2–57.6) | 42.2 (36.2–48.0) | 65.8 (58.7–72.1) | 0.288 |
| SRC | 33.4 (31.6–35.2) | 33.3 (31.3–35.3) | 37.7 (29.6–45.8) | 26.9 (21.1–33.0) | 40.2 (31.1–49.0) | <0.001 |
| Surgery | 37.9 (36.6–39.2) | 39.2 (37.8–40.6) | 33.4 (26.3–40.6) | 25.4 (21.3–29.8) | 35.5 (28.7–42.3) | <0.001 |
| SR | 33.4 (32.2–34.6) | 34.2 (32.9–35.5) | 33.9 (27.3–40.5) | 22.3 (18.7–26.2) | 36.8 (30.8–42.8) | <0.001 |
| Radiation | 26.8 (25.1–28.5) | 27.8 (26.0–29.7) | 34.3 (24.4–44.5) | 12.5 (8.5–17.0) | 30.8 (22.4–39.5) | 0.087 |
| RC | 19.2 (15.3–23.4) | 18.9 (14.5–23.7) | 26.5 (8.5–48.9) | 18.6 (9.6–29.9) | 13.1 (3.27–29.8) | 0.184 |
Cancers diagnosed in the period of 1973–2008, and followed up to 12/31/2013 in the SEER 18 database. In each cell, estimated rate (95% confidence interval).